Table 2 Patient characteristics
Reference | % female | Mean age in years (SD) [range] | Cancer site (%) | Common chemotherapeutic agents* (%) |
|---|---|---|---|---|
Hesketh [18] | 71 | Median 54 (NR) [25–81] | Breast (55), other (45) | Doxorubicin (15), cyclophosphamide (26), 5-FU (43), vincristine (23), methotrexate (14) |
Gralla [19] | 72 | 55 (11) [18-NR] | Breast (57), lung (80 < bladder (5), colon (4), rectal (3), small-cell lung (3), gastric (3) | Cyclophosphamide (63), doxorubicin (48), cisplatin (18), methotrexate (16), carboplatin (12) |
Kim [20] | 37 | 55.6 (11) [18-NR] | Lung (26), gastric (11), other (29) | 5-FU plus cisplatin (27), cisplatin plus the following: taxol, docetaxel, etoposide and ifosfomide, etoposide, gemcitabine, docetaxel plus 5-FU (73) |